KR100970455B1 - Method for preparing extract of ginseng using ultra high pressure - Google Patents
Method for preparing extract of ginseng using ultra high pressure Download PDFInfo
- Publication number
- KR100970455B1 KR100970455B1 KR1020080012278A KR20080012278A KR100970455B1 KR 100970455 B1 KR100970455 B1 KR 100970455B1 KR 1020080012278 A KR1020080012278 A KR 1020080012278A KR 20080012278 A KR20080012278 A KR 20080012278A KR 100970455 B1 KR100970455 B1 KR 100970455B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- red ginseng
- pressure
- ginsenoside
- enzyme
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 36
- 239000000284 extract Substances 0.000 title claims description 23
- 241000208340 Araliaceae Species 0.000 title abstract description 56
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title abstract description 56
- 235000003140 Panax quinquefolius Nutrition 0.000 title abstract description 56
- 235000008434 ginseng Nutrition 0.000 title abstract description 56
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 68
- 108090000790 Enzymes Proteins 0.000 claims abstract description 55
- 102000004190 Enzymes Human genes 0.000 claims abstract description 55
- 229940088598 enzyme Drugs 0.000 claims abstract description 55
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 48
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 40
- 108010059820 Polygalacturonase Proteins 0.000 claims abstract description 35
- 108010093305 exopolygalacturonase Proteins 0.000 claims abstract description 35
- 238000000605 extraction Methods 0.000 claims abstract description 32
- 108010059892 Cellulase Proteins 0.000 claims abstract description 16
- 229940106157 cellulase Drugs 0.000 claims abstract description 16
- 101710130006 Beta-glucanase Proteins 0.000 claims abstract description 13
- 229920002678 cellulose Polymers 0.000 claims abstract description 13
- 239000001913 cellulose Substances 0.000 claims abstract description 13
- 229940059442 hemicellulase Drugs 0.000 claims abstract description 13
- 108010002430 hemicellulase Proteins 0.000 claims abstract description 13
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 229920002488 Hemicellulose Polymers 0.000 claims description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 10
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 10
- 235000013402 health food Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 7
- -1 Hydrolysis Proteins 0.000 abstract description 6
- 230000007062 hydrolysis Effects 0.000 abstract description 6
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 6
- 101100189586 Mus musculus Pde6a gene Proteins 0.000 abstract 1
- 101150030922 mpa gene Proteins 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 52
- 235000000346 sugar Nutrition 0.000 description 27
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 22
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 19
- 235000020710 ginseng extract Nutrition 0.000 description 17
- 229930182490 saponin Natural products 0.000 description 11
- 150000007949 saponins Chemical class 0.000 description 11
- 235000017709 saponins Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 description 10
- 235000013824 polyphenols Nutrition 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 235000008504 concentrate Nutrition 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 3
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 2
- AQFATCCHOXBYNK-UHFFFAOYSA-N 2-piperidin-1-ium-1-ylethyl 1-cyclohexylcyclohexane-1-carboxylate;chloride Chemical compound [Cl-].C1CCCCC1(C1CCCCC1)C(=O)OCC[NH+]1CCCCC1 AQFATCCHOXBYNK-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000223262 Trichoderma longibrachiatum Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 description 1
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000223198 Humicola Species 0.000 description 1
- 241001480714 Humicola insolens Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 150000002009 diols Chemical group 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000004072 triols Chemical group 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/46—Ultra high pressure
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
20 내지 110MPa의 압력 하에서 인삼으로부터 진세노사이드를 추출하며, 추출 전 또는 추출과 동시에 베타-글루카네이즈(β-glucanase), 펙티네이즈(pectinase), 헤미셀룰레이즈(hemicellulase), 셀룰레이즈(cellulase), 아라비네이즈(arabinase) 및 자일라네이즈(xylanase)로 구성된 군으로부터 선택된 하나 이상의 효소를 가하여 인삼을 가수분해시킴으로써 진세노사이드의 추출 효율을 극대화시킬 수 있는 추출방법이 개시된다.Ginsenosides are extracted from ginseng under a pressure of 20 to 110 MPa, and beta-glucanase, pectinase, hemicellulase and cellulase before or simultaneously with extraction. Disclosed is an extraction method capable of maximizing ginsenoside extraction efficiency by hydrolyzing ginseng by adding one or more enzymes selected from the group consisting of arabinase and xylanase.
초고압, 진세노사이드, 인삼, 홍삼, 효소, 가수분해, 펙티네이즈, Rg2, Rg3, Rb1, 셀룰레이즈 Ultra High Pressure, Ginsenoside, Ginseng, Red Ginseng, Enzyme, Hydrolysis, Pectinase, Rg2, Rg3, Rb1, Cellulose
Description
본 발명은 인삼 추출물을 제조하는 방법에 관한 것이다. 더 상세하게는 본 발명은 진세노사이드의 함량이 높은 인삼 추출물을 제조하는 방법에 관한 것이다. 본 발명은 진세노사이드 중에서 특히 Rg1, Rg2, Rg3 및 Rb1의 함량이 높은 인삼 추출물을 제조하는 방법에 관한 것이다. The present invention relates to a method for preparing a ginseng extract. More specifically, the present invention relates to a method for preparing a ginseng extract with a high content of ginsenosides. The present invention relates to a method for preparing a ginseng extract having a high content of Rg1, Rg2, Rg3 and Rb1 among ginsenosides.
인삼은 수삼, 백삼, 홍삼, 산삼, 장뇌, 미삼, 원삼 등을 모두 포함하는 가장 넓은 개념이다. 인삼은 중국 등 한방의학에서 매우 가치가 높은 의약품으로 이용되어온 천연물 소재이다. 수많은 의서에 인삼의 약효가 수록되어 있다. 그러나 실제로 장구한 이용의 역사에도 불구하고 임상연구를 통한 과학적인 규명은 부족한 형편이다. 그럼에도 불구하고 현대 의학이 소개된 지금도 보약으로서 인삼의 인기가 떨어지지 않고, 건강기능식품 중 부동의 1위를 차지하고 있는 것은 오랜 임상 역사가 인정하는 약효를 나타내고 부작용이 적으며 안전도가 높은 생약이란 이유일 것이다.Ginseng is the broadest concept that includes ginseng, white ginseng, red ginseng, wild ginseng, camphor, rice ginseng, and original ginseng. Ginseng is a natural product that has been used as a very valuable medicine in oriental medicine, such as China. Many documents contain the effects of ginseng. However, despite the long history of use, scientific identification through clinical research is insufficient. Nevertheless, even though modern medicine has been introduced, the popularity of ginseng as a medicine is not falling, and it is the first place among the health functional foods. .
인삼의 주된 기능성 성분은 식물체의 여러 사포닌 중 인삼 사포닌만을 특별하게 구분하여 명명한 "진세노사이드(ginsenoside)"라 불리우는 인삼 사포닌이다. The main functional ingredient of ginseng is ginseng saponin called "ginsenoside" which is specially named only ginseng saponin among various saponins of plants.
인삼 성분에 대한 과학적인 연구가 시작된 것은 1960년대 이후라고 볼 수 있다. 사포닌의 화학구조를 보면 크게 당부분(glycone)과 비당부분(aglycone)으로 구성된 배당체이다. 이러한 사포닌이 체내에서 흡수될 때는 사람의 장내에 있는 특유 미생물에 의해 분해되어 체내로 흡수 되어진다. 하지만 인삼 사포닌을 분해하는 장내 미생물은 사람의 체질에 따라 그리고 식습관 따라 그 존재의 유무와 보유하고 있는 정도가 다르다. 이로 인해 인삼의 복용 후 사람마다 효능의 차이가 나타날 수 있다. 어떤 사람은 사포닌 중 디올(diol) 형태만을 흡수하고, 어떤 사람은 트리올(triol) 형태만을 흡수하며, 어떤 사람은 인삼 사포닌을 전혀 흡수를 하지 못하게 된다.Scientific research on ginseng components began after the 1960s. The chemical structure of saponins is a glycoside that consists of sugar and aglycone. When these saponins are absorbed by the body, they are broken down by the unique microorganisms in the human intestine and absorbed into the body. However, the intestinal microorganisms that break down ginseng saponins differ depending on the human constitution and dietary habits, and their presence and degree of retention. This can cause differences in efficacy after taking ginseng. Some people only absorb the diol form of saponins, some people only absorb the triol form, and some people do not absorb ginseng saponins at all.
백삼과 홍삼의 성분의 차이는 함유된 진세노사이드 종류와 함량의 차이이다. 백삼에는 진세노사이드 Ra, Rb1, Rb2, Rc, Rg1, Re 등이 주로 함유되어 있다. 홍삼은 상기 백삼에 있는 성분들이 찌는 과정에서 물리화학적 전환체가 형성된다. 예컨대, 찌는 과정에서 진세노사이드 Rg3가 다량 생성된다. 그 외에도 홍삼에는 진세노사이드 Rh2, Rh1 등을 소량 함유하고 있다. 이러한 성분들은 서로 전혀 다른 생리활성을 갖고 있다. 백삼은 분자량이 큰 다당체를 많이 함유하고 있지만, 산성다당체는 홍삼에 비해 낮다. 홍삼에는 분자량이 백삼에 비해 작은 다당체를 다량 함유하고 있다.The difference between white ginseng and red ginseng is the difference in the content and content of ginsenosides contained. White ginseng mainly contains ginsenosides Ra, Rb1, Rb2, Rc, Rg1, Re and the like. The red ginseng forms a physicochemical converter in the process of steaming the components in the white ginseng. For example, a large amount of ginsenoside Rg3 is produced in the steaming process. In addition, red ginseng contains small amounts of ginsenosides Rh2 and Rh1. These ingredients have different biological activities. White ginseng contains high molecular weight polysaccharides, but acidic polysaccharides are lower than red ginseng. Red ginseng contains a large amount of polysaccharide whose molecular weight is smaller than that of white ginseng.
인삼의 주성분은 사포닌인 진세노사이드들이며 프로토파낙사디 올(protopanaxadiol)계인 진세노사이드 Rb1, Rb2, Rc 등과 프로토파낙사트리올(protopanaxatriol)계인 진세노사이드 Re, Rg1, Rf 등이 알려져 있다. 이 성분들의 대표적인 약리작용으로는 항암 활성, 항염증, 항당뇨 작용 등을 들 수 있다. 이 성분들을 가지고 직접 암세포를 이용하여 인 비트로(in vitro)에서 항암 활성 등을 측정하면 활성이 없다. 그러나, 이 성분들이 경구 투여되는 경우에는 장내세균의 대사를 받아 컴파운드 케이(compound K)와 같은 화합물로 전환되면 강한 암세포 독성과 암전이 억제 활성을 나타낸다. The main components of ginseng are ginsenosides, which are saponins, and ginsenosides Rb1, Rb2, and Rc, which are protopanaxadiols, and ginsenosides Re, Rg1, and Rf, which are protopanaxatriols, are known. Representative pharmacological actions of these components include anti-cancer activity, anti-inflammatory, anti-diabetic action. With these components, using cancer cells directly to measure anti-cancer activity in vitro ( in vitro ), there is no activity. However, when these components are administered orally, they are metabolized by enterobacteriaceae and converted to compounds such as compound K, which shows strong cancer cell toxicity and cancer metastasis inhibitory activity.
진세노사이드가 상기한 장내세균의 대사를 받는 과정을 보면 다음과 같다. 먼저 프로토파낙사디올(protopanaxadiol)계 화합물인 진세노사이드 Rb1, Rb2, Rc 등은 진세노사이드 F2를 경유하여 컴파운드(compound) K로 대사된다. 이러한 대사 반응은 장내 우세균인 박테로이드(Bacteroides)속, 푸소박테이룸(Fusobacterium)속, 프로베텔라(Provetella)속 균주 등에 의해 촉매된다. 또한 프로토파낙사트리올(protopanaxatriol)계 화합물인 진세노사이드 Re, Rg1, Rf 등은 상기 균주들에 의해 진세노사이드 Rh1 또는 F1로 대사되고 더 나아가 프로토파낙사트리올(protopanaxatriol)로 대사된다.When ginsenosides are metabolized by the intestinal bacteria described above, they are as follows. First, ginsenosides Rb1, Rb2, and Rc, which are protopanaxadiol-based compounds, are metabolized into compound K via ginsenoside F2. This metabolic reaction is catalyzed by strains of the genus Bacteroides , Fusobacterium genus, Provetella genus, and the like. In addition, ginsenosides Re, Rg1, Rf, etc., which are protopanaxatriol-based compounds, are metabolized to ginsenosides Rh1 or F1 by the strains, and further metabolized to protopanaxatriol.
물리화학적인 방법에 의해서도 인삼의 성분들이 전환될 수 있다. 예를 들면 인삼 중의 진세노사이드 Rb1, Rb2, Rc 등은 열처리에 의해 진세노사이드 Rg3로 전환될 수 있다. 이렇게 전환된 인삼 사포닌을 함유한 인삼을 복용하게 되면 장내에서 장내세균에 의해 진세노사이드 Rh2로 전환될 수 있고 나아가 프로토파낙사디올(protopanxadiol)로 전환될 수 있다.The components of ginseng can also be converted by physicochemical methods. For example, ginsenosides Rb1, Rb2, Rc, etc. in ginseng may be converted to ginsenoside Rg3 by heat treatment. Taking ginseng containing the converted ginseng saponin can be converted to ginsenoside Rh2 by intestinal bacteria in the intestine and further converted to protopanxadiol.
상기와 같은 성분의 차이는 인삼 약효의 차이와 밀접한 관계가 있다. 만약, 진세노사이드 Rb1, Rb2, Rc가 많이 함유된 백삼의 경우에는 컴파운드 K가 혈액 중으로 많이 이행될 수 있다. 한편, 진세노사이드 Rg3가 많은 홍삼의 경우에는 진세노사이드 Rh2가 혈액 중으로 많이 이행될 수 있다. 그 외에 다른 인삼 사포닌들 역시 혈액 중으로 이행되는 양상이 다를 수 있으므로, 인삼의 약효를 평가함에 있어 상기와 같은 점을 고려해야 한다. The difference between the ingredients is closely related to the difference in ginseng drug efficacy. If ginsenosides Rb1, Rb2, Rc containing a lot of white ginseng compound K can be transferred to the blood. On the other hand, in the case of red ginseng with a lot of ginsenoside Rg3, ginsenoside Rh2 can be transferred to the blood. In addition to other ginseng saponins may also be different in the transition to the blood, so in evaluating the efficacy of ginseng should be considered as above.
추출은 식물체로부터 유용성분을 분리하는 가장 중요한 공정이다. 인삼으로부터 유용성분인 진세노사이드를 추출하기 위해 많은 추출방법들이 사용되었다. 전통적인 추출방법으로는 용매를 이용한 가열추출방법이다. 이러한 추출방법은 오랜시간이 소요되며, 추출효율이 낮은 단점을 지니고 있다. 게다가 많은 성분들이 열에 불안정하므로 가열 추출하는 과정 중에 파괴되는 문제점이 있다. Extraction is the most important process for separating useful components from plants. Many extraction methods have been used to extract ginsenoside, a useful ingredient from ginseng. The conventional extraction method is a heating extraction method using a solvent. This extraction method takes a long time and has the disadvantage of low extraction efficiency. In addition, many of the components are heat instable and thus have a problem of being destroyed during the heat extraction process.
이러한 단점을 보완하고자 도입된 신기술 중 하나로서 초음파를 활용한 추출방법이 있다. 초음파 추출은 에너지를 용매에 신속히 전달할 뿐만 아니라 추출 대상 시료에 직접적으로 전달할 수 있다. 즉, 초음파 기술은 추출용매의 효율을 높일 수 있으며, 음파진동의 기계적 충격에 의해 세포막이 파괴되어 세포 내용물의 용출을 용이하게 한다. 그러나 이러한 방법은 산업적으로 적용하기가 어려운 문제점이 있다. One of the new technologies introduced to compensate for these drawbacks is the extraction method using ultrasonic waves. Ultrasonic extraction can deliver energy quickly to the solvent as well as directly to the sample to be extracted. That is, the ultrasonic technology can increase the efficiency of the extraction solvent, the cell membrane is destroyed by the mechanical shock of the sonic vibration to facilitate the elution of the cell contents. However, this method has a problem that is difficult to apply industrially.
한편, 이산화탄소를 이용한 초임계추출 방법이 사용되기도 한다. 이 방법은 지용성물질의 추출에는 용이하나 수용성 성분의 추출에는 한계점이 있다. 이러한 새로운 기술들은 추출에 장시간이 요하거나 많은 에너지를 소비하는 문제를 지니고 있다.On the other hand, supercritical extraction method using carbon dioxide is also used. This method is easy to extract fat-soluble substances but has limitations in extracting water-soluble components. These new technologies have problems that require a long time to extract or consume a lot of energy.
본 발명의 일실시예의 목적은 인삼 추출물을 제공하는 것이다. An object of one embodiment of the present invention is to provide a ginseng extract.
본 발명의 다른 일실시예의 목적은 진세노사이드 함량이 높은 인삼 추출물을 제공하는 것이다. Another object of an embodiment of the present invention is to provide a ginseng extract with a high ginsenoside content.
본 발명의 또 다른 일실시예의 목적은 진세노사이드 중에서 특히, Rg1의 함량이 높은 인삼 추출물을 제공하는 것이다. It is an object of another embodiment of the present invention to provide a ginseng extract having a high content of Rg1, in particular among ginsenosides.
본 발명의 또 다른 일실시예의 목적은 진세노사이드 중에서 특히, Rg2의 함량이 높은 인삼 추출물을 제공하는 것이다. It is an object of another embodiment of the present invention to provide a ginseng extract having a high content of Rg2, in particular among ginsenosides.
본 발명의 또 다른 일실시예의 목적은 진세노사이드 중에서 특히, Rg3의 함량이 높은 인삼 추출물을 제공하는 것이다. It is an object of another embodiment of the present invention to provide a ginseng extract having a high content of Rg3, in particular among ginsenosides.
본 발명의 또 다른 일실시예의 목적은 진세노사이드 중에서 특히, Rb1의 함량이 높은 인삼 추출물을 제공하는 것이다. It is an object of another embodiment of the present invention to provide a ginseng extract having a high content of Rb1 among ginsenosides.
본 발명의 일실시예에 따른 초고압을 이용한 인삼 추출물의 제조방법은 20 내지 110MPa의 압력 하에서 인삼으로부터 진세노사이드를 추출하는 것을 포함하는 것을 특징으로 한다. Method for preparing ginseng extract using ultra-high pressure according to an embodiment of the present invention is characterized in that it comprises extracting ginsenoside from ginseng under a pressure of 20 to 110MPa.
본 발명의 다른 일실시예에 따른 초고압을 이용한 인삼 추출물의 제조방법에 있어서, 상기 추출 전 또는 추출과 동시에 베타-글루카네이즈(β-glucanase), 펙티 네이즈(pectinase), 헤미셀룰레이즈(hemicellulase), 셀룰레이즈(cellulase), 아라비네이즈(arabinase) 및 자일라네이즈(xylanase)로 구성된 군으로부터 선택된 하나 이상의 효소를 가하여 인삼을 가수분해시키는 것을 포함하는 것을 특징으로 한다.In the method of preparing ginseng extract using ultra high pressure according to another embodiment of the present invention, beta-glucanase (p-glucanase), pectinase, hemicellulase (hemicellulase) before or simultaneously with the extraction And hydrolyzing ginseng by adding one or more enzymes selected from the group consisting of cellulase, arabinase and xylanase.
본 발명의 일실시예에 따른 건강식품 조성물은 20 내지 110MPa의 압력 하에서 인삼으로부터 진세노사이드를 추출하는 것을 포함하는 방법에 의해 제조된 인삼 추출물을 유효성분으로 포함하는 것을 특징으로 한다. Health food composition according to an embodiment of the present invention is characterized in that it comprises a ginseng extract prepared by a method comprising extracting ginsenoside from ginseng under a pressure of 20 to 110MPa as an active ingredient.
본 발명의 또 다른 일실시예에 따른 건강식품 조성물은 20 내지 110MPa의 압력 하에서 추출 전 또는 추출과 동시에 베타-글루카네이즈(β-glucanase), 펙티네이즈(pectinase), 헤미셀룰레이즈(hemicellulase), 셀룰레이즈(cellulase), 아라비네이즈(arabinase) 및 자일라네이즈(xylanase)로 구성된 군으로부터 선택된 하나 이상의 효소를 가하여 인삼을 가수분해시키는 것을 포함하는 방법에 의해 제조된 인삼 추출물을 유효성분으로 포함하는 것을 특징으로 한다. Health food composition according to another embodiment of the present invention is beta-glucanase (β-glucanase), pectinase (hemicellulase), before or at the same time before extraction under a pressure of 20 to 110MPa, Comprising ginseng extract prepared by a method comprising hydrolyzing ginseng by adding at least one enzyme selected from the group consisting of cellulase, arabinase and xylanase, as an active ingredient It features.
본 발명을 이용하면 진세노사이드의 함량이 높은 인삼 추출물을 얻을 수 있다. 특히, 진세노사이드 중에서 Rg1, Rg2, Rg3 및 Rb1의 함량이 높은 인삼 추출물을 얻을 수 있다. Using the present invention can be obtained a ginseng extract with a high content of ginsenosides. In particular, ginseng extract with a high content of Rg1, Rg2, Rg3 and Rb1 in ginsenosides can be obtained.
본 발명은 추출 효율을 높이기 위하여 초고압 반응을 도입한 것이다. "초고 압" 이란 2~3만 atm을 초과하는 높은 압력으로서, 실용화된 장비를 이용하면 1000만 atm 정도를 얻을 수 있다. The present invention introduces an ultra-high pressure reaction in order to increase the extraction efficiency. "Ultra-high pressure" is a high pressure of more than 2 to 30,000 atm, using practical equipment can achieve about 10 million atm.
초고압 반응기는 상용화되어 있으므로, 상업적으로 판매되고 있는 초고압 반응기를 이용할 수 있다. 예컨대, 일본 동양고압사의 DFS-2L 등을 사용할 수 있다. Since the ultrahigh pressure reactor is commercialized, it is possible to use a commercially available ultrahigh pressure reactor. For example, DFS-2L etc. of Toyo Japan High Pressure, Inc. can be used.
본 발명의 일실시예에 따른 인삼 추출물의 제조방법에 있어서, 압력은 20 내지 110MPa인 것이 바람직하다. 20MPa 미만이면 추출 효율이 미미하고, 110MPa을 초과하면 추출 효율 증가 폭이 둔화되어 비경제적이거나 특정 성분의 경우 추출 효율이 오히려 떨어지기 때문이다. In the production method of ginseng extract according to an embodiment of the present invention, the pressure is preferably 20 to 110MPa. If it is less than 20MPa extraction efficiency is insignificant, and if it exceeds 110MPa, the extraction efficiency increase is slowed down, which is uneconomical or the extraction efficiency is deteriorated for certain components.
진세노사이드 Rg1의 경우, 펙티네이즈(pectinase), 헤미셀룰레이즈(hemicellulase) 및 셀룰레이즈(cellulase)로 이루어진 군으로부터 선택된 하나 이상의 효소를 사용하는 것이 바람직하다. 가장 바람직하게는 펙티네이즈이다. 이 때 바람직한 추출 시의 압력은 20 내지 40MPa 또는 90 내지 110MPa이다. 상기 범위를 벗어나면 추출 효율이 떨어진다. In the case of ginsenoside Rg1, it is preferable to use at least one enzyme selected from the group consisting of pectinase, hemicellulase and cellulase. Most preferably pectinase. At this time, a preferable extraction pressure is 20 to 40 MPa or 90 to 110 MPa. Outside the above range, the extraction efficiency is lowered.
진세노사이드 Rg3의 경우, 베타-글루카네이즈(β-glucanase), 펙티네이즈(pectinase), 헤미셀룰레이즈(hemicellulase) 및 셀룰레이즈(cellulase)로 이루어진 군으로부터 선택된 하나 이상의 효소를 사용하는 것이 바람직하다. 이 경우 추출 시의 압력은 40 내지 90MPa인 것이 바람직하다. 상기 압력 범위를 벗어나면 추출 효율이 떨어진다. 가장 바람직하게는 70 내지 90MPa의 압력 하에서 셀룰레이즈로 가수분해하는 것이다. For ginsenoside Rg3, it is preferable to use at least one enzyme selected from the group consisting of beta-glucanase, pectinase, hemicellulase and cellulase. . In this case, the pressure at the time of extraction is preferably 40 to 90 MPa. Outside the pressure range, the extraction efficiency is lowered. Most preferably hydrolyzed to cellulose under a pressure of 70 to 90 MPa.
진세노사이드 Rg2의 경우, 가수분해 효소로서 펙티네이즈를 사용하는 것이 바람직하다. 추출 시의 압력은 90 내지 110MPa인 것이 바람직하다. 상기 압력 범위를 벗어나면 추출 효율이 떨어진다. In the case of ginsenoside Rg2, it is preferable to use pectinase as a hydrolase. The pressure at the time of extraction is preferably 90 to 110 MPa. Outside the pressure range, the extraction efficiency is lowered.
진세노사이드 Rb1의 경우, 추출 시의 압력은 20 내지 40MPa 또는 90 내지 110MPa인 것이 바람직하다. 상기 압력 범위를 벗어나면 추출 효율이 떨어진다. 효소는 펙티네이즈, 헤미셀룰레이즈 및 셀룰레이즈의 조합, 또는 펙티네이즈 단독을 사용하는 것이 바람직하다. 가장 바람직하게는 추출 시의 압력이 20 내지 40MPa이면서 효소로는 펙티네이즈, 헤미셀룰레이즈 및 셀룰레이즈의 조합을 사용하거나, 추출 시의 압력이 90 내지 110MPa이면서 효소로는 펙티네이즈 단독을 사용하는 것이다. In the case of ginsenoside Rb1, the pressure at the time of extraction is preferably 20 to 40 MPa or 90 to 110 MPa. Outside the pressure range, the extraction efficiency is lowered. The enzyme is preferably used a combination of pectinase, hemicellulose and cellulose, or pectinase alone. Most preferably, a combination of pectinase, hemicellulose and cellulose is used as the enzyme when the extraction pressure is 20 to 40 MPa, or pectinase alone is used as the enzyme when the extraction pressure is 90 to 110 MPa. .
본 발명의 일실시예에서 인삼을 가수분해하기 위해 사용되는 효소인 셀룰레이즈의 예로서, 트리코더마(Tricholderma)속에서 유래된 셀룰레이즈를 들 수 있다. 트리코더마(Tricholderma)속 유래 셀룰레이즈로는 Econase CE (AB Enzymes GmbH, Darmstadt, Germany)를 들 수 있다. Econase CE의 최적 pH는 4.0 내지 5.5이며, 최적 온도는 55℃이다.As an example of cellulose which is an enzyme used to hydrolyze ginseng in one embodiment of the present invention, cellulose derived from the genus Tricholderma may be mentioned. Cellulase derived from the genus Tricholderma includes Econase CE (AB Enzymes GmbH, Darmstadt, Germany). The optimum pH of Econase CE is 4.0 to 5.5 and the optimum temperature is 55 ° C.
셀룰레이즈 활성을 갖는 또 다른 효소를 예를 들면, Rapidase (DSM, Delft, Netherlands) 및 Viscozyme (Novozymes, Dittingen, Switzerland)을 들 수 있다. Rapidase는 아스퍼질러스 나이저(Asp. Niger) 또는 티. 롱기브라키아툼(T. longibrachiatum)으로부터 유래된 효소로서, 셀룰레이즈 활성 이외에도 펙티네이즈(pectinase), 헤미셀룰레이즈(hemicellulase) 활성을 갖고 있다. Rapidase의 최적 pH는 4.0 내지 5.0이고, 최적 온도는 10 내지 55℃이다. Viscozyme은 아스 프.(Asp.) 속으로부터 유래된 효소로서, 셀룰레이즈 활성 이외에도 아라비네이즈(arabinase), 베타-글루카네이즈(β-glucanase), 헤미셀룰레이즈(hemicellulase), 자일라네이즈(xylanase) 활성을 갖고 있다. Other enzymes with cellulase activity include, for example, Rapidase (DSM, Delft, Netherlands) and Viscozyme (Novozymes, Dittingen, Switzerland). Rapidase is known as Aspergillus Niger or T. An enzyme derived from T. longibrachiatum , which has pectinase and hemicellulase activity in addition to cellulase activity. The optimum pH of Rapidase is 4.0 to 5.0 and the optimum temperature is 10 to 55 ° C. Viscozyme is an enzyme derived from the genus Asp. , In addition to cellulase activity, arabiase, beta-glucanase, hemicellulase and xylanase Has activity.
본 발명의 다른 일실시예에서는 인삼을 가수분해하기 위한 효소로서 펙티네이즈를 사용할 수 있다. 펙티네이즈의 예로서, Cytolase PCL 5 (Gist-Brocades, Seclin, France)를 들 수 있다. Cytolase PCL 5는 아스프. 니거(Asp. Niger)로부터 유래된 펙티네이즈로서, 최적 pH는 2.5 내지 5.0이고 최적 온도는 10 내지 55℃이다. 상기 언급한 Rapidase 역시 펙티네이즈의 활성을 갖고 있으므로 본 실시예에서 인삼을 가수분해하기 위한 펙티네이즈로서 사용될 수 있다. In another embodiment of the present invention, pectinase may be used as an enzyme for hydrolyzing ginseng. As an example of pectinase, Cytolase PCL 5 (Gist-Brocades, Seclin, France) is mentioned. Cytolase PCL 5 is Asph. As pectinase derived from Asp. Niger , the optimum pH is 2.5 to 5.0 and the optimum temperature is 10 to 55 ° C. Rapidase mentioned above also has the activity of pectinase and thus can be used as pectinase for hydrolyzing ginseng in this embodiment.
본 발명의 또 다른 일실시예에서는 인삼을 가수분해하기 위한 효소로서 헤미셀룰레이즈를 사용할 수 있다. 헤미셀룰레이즈로서 앞서 언급한 Rapidase 또는 Viscozyme을 사용할 수 있다. In another embodiment of the present invention, hemicellulose may be used as an enzyme for hydrolyzing ginseng. As hemicellulose, the above-mentioned Rapidase or Viscozyme can be used.
본 발명의 또 다른 일실시예에서는 인삼을 가수분해하기 위한 효소로서 베타-글루카네이즈(β-glucanase)를 사용할 수 있다. 베타-글루카네이즈의 예로 Ultraflo L (Novozymes, Dittingen, Switzerland)을 들 수 있다. Ultraflo L은 휴미콜라 인솔렌즈(Humicola insolens)로부터 유래된 효소로서 최적 pH가 6이고 최적 온도는 40℃이다. 앞서 언급한 Viscozyme 역시 베타-글루카네이즈 활성을 갖고 있으므로, 상기 Ultraflo L 대신 Viscozyme을 사용할 수도 있다. In another embodiment of the present invention, beta-glucanase may be used as an enzyme for hydrolyzing ginseng. An example of beta-glucanase is Ultraflo L (Novozymes, Dittingen, Switzerland). Ultraflo L is an enzyme derived from Humicola insolens with an optimal pH of 6 and an optimum temperature of 40 ° C. Since Viscozyme mentioned above also has beta-glucanase activity, Viscozyme may be used instead of Ultraflo L.
그 외 본 발명의 또 다른 일실시예에서 사용될 수 있는 효소는 아라비네이즈(arabinase), 자일라네이즈(xylanase) 등을 들 수 있다. Other enzymes that may be used in another embodiment of the present invention include arabinase, xylanase, and the like.
진세노사이드 Rg1은 면역기능 증강작용, 혈소판 응집억제, 항트롬빈, 기억 및 학습기능 증진작용, 단백질합성 촉진작용, 항피로 작용, 항스트레스작용, 중추 흥분작용, 혈관확장작용, 고온환경 및 내인성 발열물질 등 유해자극 방어작용, 스트레스성 성 행동장해 개선작용, 항 신염작용 및 신 혈류량 증대작용, 신경세포 생존율 촉진작용, 콜레스테롤 대사 촉진작용, 항염증 작용, 간 세포 증식 및 DNA 합성촉진, 간 장해 보호작용, 부신피질자극 호르몬 분비 촉진작용 등을 수행한다. Rg1은 인삼에 펙티네이즈, 헤미셀룰레이즈 및 셀룰레이즈로부터 선택된 하나 이상의 효소로 가수분해하는 것이 바람직하다. 특히 바람직하게는 20 내지 40MPa 또는 90 내지 110MPa의 압력 하에서 펙티네이즈를 이용하여 가수분해시키는 것이다. Ginsenoside Rg1 is an immune function enhancing, platelet aggregation inhibitory, antithrombin, memory and learning function, protein synthesis, anti-fatigue, antistress, central excitatory, vasodilation, high temperature environment and endogenous fever Protective actions against harmful stimuli such as substances, improvement of stressful behavioral disorders, anti-inflammatory and renal blood flow enhancement, neuronal cell survival rate, cholesterol metabolism, anti-inflammatory, liver cell proliferation and DNA synthesis promotion, liver protection It acts, stimulating the secretion of adrenal cortex stimulating hormone. Rg1 is preferably hydrolyzed to one or more enzymes selected from pectinase, hemicellulose and cellulose in ginseng. Especially preferably, hydrolysis is performed using pectinase under a pressure of 20 to 40 MPa or 90 to 110 MPa.
진세노사이드 Rg2는, 백삼에는 존재하지 않고 홍삼에만 소량 존재하는 진세노사이드이다. Rg2는 혈소판 응집 억제, 아세틸콜린 유도 카테콜아민 분비 억제 및 세포내 칼슘 유입 억제, 항 트롬빈, 기억 감퇴 개선, 평활근 세포 증식 억제 작용 등을 한다. 인삼에 펙티네이즈를 처리하여 가수분해시키면 Rg2의 함량을 현저히 증가시킬 수 있다. 또한, 인삼에 셀룰레이즈 또는 헤미셀룰레이즈를 처리하는 경우에도 Rg2의 함량을 상당히 높은 수준으로 증가시킬 수 있다. Ginsenoside Rg2 is ginsenoside which does not exist in white ginseng but exists only in red ginseng. Rg2 inhibits platelet aggregation, inhibits acetylcholine induced catecholamine secretion, inhibits intracellular calcium influx, antithrombin, memory decay, and smooth muscle cell proliferation. Hydrolysis by treating ginseng with pectinase can significantly increase the content of Rg2. In addition, the treatment of ginseng with cellulose or hemicellulose can also increase the Rg2 content to significantly higher levels.
진세노사이드 Rg3 역시 백삼에는 존재하지 않고 홍삼에만 소량 존재한다. Rg3은 암세포 전이 억제 작용, 혈소판 응집 억제 및 항혈전 작용, 간 상해 억제 작용, 혈관 이완 작용, 항암제의 내성 억제 작용, 뇌신경 보호 등을 한다. 인삼에 펙티네이즈를 처리하여 가수분해하는 경우에 Rg3의 함량을 현저히 증가시킬 수 있다. 그 외, 베타-글루카네이즈, 셀룰레이즈 또는 헤미셀룰레이즈를 처리하는 경우에도 Rg3의 함량을 상당히 높은 수준으로 증가시킬 수 있다. Ginsenoside Rg3 also does not exist in white ginseng, but only in small amounts in red ginseng. Rg3 inhibits cancer cell metastasis, inhibits platelet aggregation and antithrombosis, inhibits liver injury, vascular relaxation, inhibits resistance of anticancer drugs, and protects nerves. When ginseng is hydrolyzed by treating pectinase, the content of Rg3 can be significantly increased. In addition, the treatment of beta-glucanase, cellulose or hemicellulose can increase the content of Rg3 to significantly higher levels.
진세노사이드 Rb 1은 백삼이나 홍삼 모두에 다량 함유되어 있다. Rb1은 중추억제 및 정신 안정 작용, 공격성 행동억제, 진통 작용, 항경련 작용, 고콜레스테롤 저하 작용, 항불안 작용, 콜레스테롤 생합성 촉진작용, 골수세포의 DNA, RNA, 단백질 및 지질 합성 촉진 작용, 단백질 합성 촉진 작용, 신경세포 생존 촉진 작용, 아세칠콜린 방출 촉진 작용, 기억력 개선 작용, 혈소판 응집 억제 작용, 지질 과산화 억제작용, 혈관 확장작용, 콜레스테롤 대사촉진작용, 항염작용, 간 상해 보호작용 등을 한다. 진세노사이드 Rb1은 펙티네이즈, 셀룰레이즈, 헤미셀룰레이즈를 처리하여 가수분해시키는 경우에 그 함량을 상당한 수준으로 증가시킬 수 있다. Ginsenoside Rb 1 is contained in large amounts in both white and red ginseng. Rb1 inhibits central and mental stability, aggression, analgesic, anticonvulsant, hypercholesterolemic, anti-anxiety, cholesterol biosynthesis, DNA, RNA, protein and lipid synthesis, protein synthesis Promotes action, promotes neuronal survival, promotes acylcholine release, improves memory, inhibits platelet aggregation, inhibits lipid peroxidation, vasodilation, promotes cholesterol metabolism, anti-inflammatory, and protects liver injury. Ginsenoside Rb1 can increase its content to significant levels when hydrolyzed by treatment with pectinase, cellulose, hemicellulose.
그 외에 Rg1, Rf, Re, Rd, Rc, Rb2 등의 진세노사이드들도 인삼에 베타-글루카네이즈, 펙티네이즈, 헤미셀룰레이즈, 셀룰레이즈 및/또는 아라비네이즈 및 자일라네이즈로부터 선택된 하나 이상의 효소를 처리하여 가수분해시킴으로써 그 함량을 현저히 증가시킬 수 있다. In addition, ginsenosides such as Rg1, Rf, Re, Rd, Rc, Rb2 may also be selected from beta-glucanize, pectinase, hemicellulose, cellulase and / or arabinase and xylase in ginseng. By treating the enzyme with hydrolysis, its content can be significantly increased.
본 발명의 일실시예에 따른 제조방법에서는, 효소 처리에 의한 가수분해 과정이 추출 및/또는 농축 과정과 동시에 수행될 수 있다. In the preparation method according to an embodiment of the present invention, the hydrolysis process by enzyme treatment may be performed simultaneously with the extraction and / or concentration process.
본 발명의 또 다른 일실시예에 따른 제조방법에서는, 효소 처리에 의한 가수분해 과정이 추출 과정 전에 별개로 수행될 수 있다. In a manufacturing method according to another embodiment of the present invention, the hydrolysis process by enzyme treatment may be performed separately before the extraction process.
본 발명의 일실시예에 따른 건강식품 조성물은 상기에서 언급한 방법 중 어느 하나에 의해 제조된 인삼 또는 그 추출물을 유효성분으로서 포함할 수 있다. The health food composition according to one embodiment of the present invention may include ginseng or extract thereof prepared by any one of the above-mentioned methods as an active ingredient.
본 발명의 다른 일실시예에 따른 건강식품 조성물은 감마 사이클로덱스트린 을 더 포함하는 것을 특징으로 한다. 인삼은 우수한 효능에도 불구하고 특유의 쓴 맛이 큰 문제점으로 인식되고 있다. 인삼에서 쓴 맛을 유발하는 성분들을 감마 사이클로덱스트린의 공동 내에 포집시키면 인삼의 쓴 맛을 현저히 감소시킬 수 있다. 감마 사이클로덱스트린의 양은 액상의 인삼 추출물, 구체적으로 인삼 농축액을 100 중량부로 하였을 때, 감마 사이클로덱스트린의 함량은 5 내지 20중량부인 것이 바람직하다. 감마 사이클로덱스트린의 양이 5중량부 미만이면 쓴 맛 차폐 효과가 미미하고, 20중량부를 초과하면 제형 안정성과 경제성이 나빠질 수 있다. 더 바람직한 감마 사이클로덱스트린 함량 범위는 7 내지 10중량부이다. Health food composition according to another embodiment of the present invention is characterized in that it further comprises gamma cyclodextrin. Although ginseng has excellent efficacy, its unique bitter taste is recognized as a big problem. Ginseng-induced bitter taste in the cavity of gamma cyclodextrin can significantly reduce the bitter taste of ginseng. When the amount of gamma cyclodextrin is 100 parts by weight of liquid ginseng extract, specifically, ginseng concentrate, the content of gamma cyclodextrin is preferably 5 to 20 parts by weight. If the amount of gamma cyclodextrin is less than 5 parts by weight, the bitter taste masking effect is insignificant, and if it exceeds 20 parts by weight, the formulation stability and economy may be deteriorated. More preferred gamma cyclodextrin content ranges from 7 to 10 parts by weight.
이하에서는 일실시예를 들어 본 발명을 더욱 상세히 설명하고자 하나, 본 발명의 범위가 이에 한정되는 것은 아니다. Hereinafter, the present invention will be described in more detail with reference to one embodiment, but the scope of the present invention is not limited thereto.
실시예Example
<실시예1 내지 실시예 4: 홍삼 추출물의 제조><Example 1 to Example 4: Preparation of red ginseng extract>
금산에서 구입한 홍삼 분말 6 g에 인산염 완충용액(50 mM, pH 5.0) 30 mL을 가하여 현탁한 후, 45℃에서, 초고압 반응기 DFS-2L (동양고압, 일본)를 이용하여 압력을 0 MPa(비교예 1), 30 MPa(실시예 1), 50 MPa(실시예 2), 80 MPa(실시예 3), 100 MPa(실시예 4)로 조절한 상태에서 12 시간 추출을 행하였다. 상기 추출물에 80% 에탄올 300 mL을 가하여 3시간 동안 환류하여 진세노사이드를 추출하였으며, 이 환류액을 30 mL까지 농축하였다. 6 g of red ginseng powder purchased from Geumsan was suspended by adding 30 mL of phosphate buffer solution (50 mM, pH 5.0), and at 45 ° C., the pressure was increased to 0 MPa using an ultrahigh pressure reactor DFS-2L (Dongyang High Pressure, Japan). The extraction was carried out for 12 hours in the state of adjusting to Comparative Example 1), 30 MPa (Example 1), 50 MPa (Example 2), 80 MPa (Example 3), 100 MPa (Example 4). 300 mL of 80% ethanol was added to the extract to reflux for 3 hours to extract ginsenosides, and the reflux was concentrated to 30 mL.
<실험예 1: 총당, 산성당, 폴리페놀 함량 및 건물량의 측정>Experimental Example 1 Measurement of Total Sugar, Acid Sugar, Polyphenol Content and Dry Matter Content
상기 비교예 1 및 실시예 1 내지 4에 따라 얻어진 농축액에 대하여 총당, 산성당, 폴리페놀 함량 및 건물량을 측정하였다. 폴리페놀 함량은 폴린-데니스(Folin-Denis) 법(Dewanto, V., Wu, X., & Liu, R. H. (2002b). Processed sweet corn has higher antioxidant activity. Journal of Agricultural and Food Chemistry, 50, 4959-4964.)에 따라 측정하였다. Total sugar, acid sugar, polyphenol content and dry weight of the concentrates obtained according to Comparative Example 1 and Examples 1 to 4 were measured. Polyphenol content was determined by the Folin-Denis method (Dewanto, V., Wu, X., & Liu, RH (2002b) .Processed sweet corn has higher antioxidant activity.Journal of Agricultural and Food Chemistry, 50, 4959 -4964.).
총당과 산성당의 함량은 페놀-황산(phenol-sulfuric acid)법과 Blumenkrantz과 Asboe-Hansen법(Blumenkrantz, N. and Asboe-Hansen, G. (1973) Anal. Biochem., 54, 484)에 의해 측정하였다. 그 결과를 하기 표에 나타내었다. The contents of total sugar and acid sugar were measured by phenol-sulfuric acid method and menBlumenkrantz and Asboe-Hansen method (Blumenkrantz, N. and Asboe-Hansen, G. (1973) Anal. Biochem., 54, 484). . The results are shown in the table below.
(Total sugar) (mg/ml)A shrine
(Total sugar) (mg / ml)
(Uronic acid)
(㎍/ml)Acid sugar
(Uronic acid)
(Μg / ml)
(㎍/ml)Polyphenols
(Μg / ml)
상기 표에 나타난 바와 같이, 총당의 함량은 30MPa일 때 가장 높은 113.1mg/ml의 함량을 보였으나, 압력을 가하지 않은 control과 유의적인 차이는 없었다. 산성당의 함량은 100MPa의 압력을 가하였을 때 가장 높은 418.8㎍/ml 함량을 보였다. 폴리페놀의 함량은 30-50MPa 압력을 가하였을 때 431.3과 422.4㎍/ml의 함량을 보였다. 건물의 양은 압력을 가할 수록 감소되는 경향을 보였다. As shown in the table, the total sugar content was the highest 113.1mg / ml at 30MPa, but there was no significant difference from the control without pressure. The acidic sugar content showed the highest content of 418.8 µg / ml when 100 MPa was applied. The polyphenol contents were 431.3 and 422.4 µg / ml at 30-50 MPa pressure. The amount of buildings tended to decrease with pressure.
<실험예 2: 실시예 1 내지 4에 대한 진세노사이드 함량 측정>Experimental Example 2: Determination of ginsenoside content for Examples 1 to 4
상기 비교예 1 및 실시예 1 내지 4에 따라 제조된 각 농축액 1g을 평량하여 70% 에탄올 50 mL을 가하여 80℃ 진탕 배양기에서 2회 추출하고 Whatman #1 paper를 이용하여 여과하였다. 여액은 진공농축기를 이용, 감압 건조하고 50 mL의 증류수를 가하여 용해하였다. 이 용액 1 mL에 디에틸에테르 2 mL을 가하여 혼합한 후, 1500 rpm에서 10분간 원심분리하여 디에틸에테르를 제거하고 여기에 다시 물포화 부탄올을 1.5 mL 가하여 혼합한 다음 부탄올 층을 회수하였다. 3회 재 반복하여 회수한 부탄올층에 증류수 1.5 ml을 가하여 혼합하고 원심분리하여 물층을 제거하였으며 본 조작을 2회 재반복하여 수용성 불순물을 세척하였다. 이렇게 얻어진 부탄올층은 40℃에서 N2 가스를 분사하며 건조하였으며 여기에 메탄올 0.5 mL을 가한 후, 0.45 μm 멤브레인 필터로 여과하여 HPLC 분석용 시료로 사용하였다. HPLC 분석은 Prevail Carbohydrate ES 5u column(Alltech, USA)이 장착된 HPLC를 이용, ELSD로 분석하였으며 하기 표 2 및 표 3(그레디언트 테이블)에 표시한 바와 같은 조건에서 수행하였다. 한편 진세노사이드 분석 시에는 엠보연구소(대덕, 한국)에서 구입한 14종의 표준물질(compound K, Rh2, Rh1, Rg5, Rk1, Rg2, Rg3, Rg1, Rf, Re, Rd, Rb2, Rc, Rb2)을 이용하여 표준곡선을 작성하고 각 피크 면적비로부터 함량을 계산하였다. 1 g of each concentrate prepared according to Comparative Example 1 and Examples 1 to 4 was weighed out, and 50 mL of 70% ethanol was added thereto, extracted twice at 80 ° C shaking incubator, and filtered using Whatman # 1 paper. The filtrate was dried under reduced pressure using a vacuum concentrator and dissolved by adding 50 mL of distilled water. 2 mL of diethyl ether was added and mixed with 1 mL of the solution, followed by centrifugation at 1500 rpm for 10 minutes to remove diethyl ether, followed by mixing with 1.5 mL of water-saturated butanol, and then recovering the butanol layer. 1.5 ml of distilled water was added to the butanol layer, which was collected by repetition three times, and the mixture was centrifuged to remove the water layer. The butanol layer thus obtained was dried by injecting N 2 gas at 40 ° C., and 0.5 mL of methanol was added thereto, followed by filtration through a 0.45 μm membrane filter, which was used as a sample for HPLC analysis. HPLC analysis was performed by ELSD using HPLC equipped with Prevail Carbohydrate ES 5u column (Alltech, USA) and performed under the conditions as indicated in Tables 2 and 3 (Gradient Table) below. On the other hand, ginsenoside analysis includes 14 standard materials (compound K, Rh2, Rh1, Rg5, Rk1, Rg2, Rg3, Rg1, Rf, Re, Rd, Rb2, Rc, A standard curve was prepared using Rb2) and the content was calculated from each peak area ratio.
SDV50A Vacuum degasser and valve module
CTS 30 Column oven (Young-Lin Co. Ltd., Korea)SP930D Solvent delivery pump
SDV50A Vacuum degasser and valve module
CTS 30 Column oven (Young-Lin Co. Ltd., Korea)
B (Acetonitrile : Water : IPA = 67 : 21 : 12)A (Acetonitrile: Water: IPA = 80: 5: 15)
B (Acetonitrile: Water: IPA = 67: 21: 12)
(min)Time
(min)
(ml/min)Flow
(ml / min)
그 결과는 하기 표 4에 나타내었다. The results are shown in Table 4 below.
(0 MPa)Comparative Example 1
(0 MPa)
(30 MPa)Example 1
(30 MPa)
(50 MPa)Example 2
(50 MPa)
(80 MPa)Example 3
(80 MPa)
(100 MPa)Example 4
(100 MPa)
상기 표에 나타난 바와 같이, 압력이 증가할수록 진세노사이드 함량이 증가하는 경향을 보였으며, 특히 진세노사이드 성분 중 유용성분인 Rg2, Rg1의 함량 역시 압력에 따라 증가하는 경향을 보였다. 총 진세노사이드 함량 변화는 비교예1(control. 0 MPa)일 때 17054.7 ㎍/mL 인데 반하여, 압력을 가한 경우 17156.7-23075.5으로 증가하였다. 또한 식품공전의 홍삼제품의 지표물질인 Rg1과 Rb1의 함량이 비교예1(control)은 6071.8 ㎍/mL 인데 반하여, 30 MPa (실시예1), 50 MPa(실시예2), 80 MPa(실시예3) 압력을 가한 경우, 각각 6318.1, 7162.5, 8676.0 ㎍/mL의 함량으로 압력을 가할수록 증가하였으나, 100 MPa (실시예4)의 경우 6925.0 ㎍/mL 감소하였다. 또한 진세노사이드 Rb1, Rb2, Rc 경우에는 compound K가 혈액 중으로 이행되므로 이들의 함량 역시 중요하다. 이들 함량도 control(비교예1)에 비하여 압력을 가하였을 경우 10425.6-17217.4 ㎍/mL으로 증가하였다. As shown in the table, as the pressure increases, the ginsenoside content showed a tendency to increase, and in particular, the contents of the useful components Rg2 and Rg1 among the ginsenoside components also showed a tendency to increase with the pressure. The change in total ginsenoside content was 17054.7 μg / mL in Comparative Example 1 (control. 0 MPa), whereas it increased to 17156.7-23075.5 when pressure was applied. In addition, the content of Rg1 and Rb1, which are indicators of red ginseng products in the food industry, was 6071.8 ㎍ / mL in Comparative Example 1, whereas 30 MPa (Example 1), 50 MPa (Example 2), and 80 MPa (execution) Example 3) When the pressure was applied, it increased with the pressure of 6318.1, 7162.5, 8676.0 μg / mL, respectively, but decreased 6925.0 μg / mL for 100 MPa (Example 4). In addition, in the case of ginsenosides Rb1, Rb2, Rc, the content of these compounds is also important because compound K is transferred into the blood. These contents also increased to 10425.6-17217.4 ㎍ / mL when pressure was applied compared to the control (Comparative Example 1).
이와 같이 고압반응을 이용하여 홍삼을 추출할 경우 홍삼 추출물의 진세노사이드의 함량이 증가하는 것을 확인하였다.As such, when the red ginseng was extracted using the high pressure reaction, the content of ginsenosides of the red ginseng extract was increased.
<실시예 5 내지 9 : 고압과 효소의 병용에 의한 추출물 제조><Examples 5 to 9: Preparation of extract by using a combination of high pressure and enzyme>
금산에서 구입한 홍삼 분말 6 g에 인산염 완충용액(50 mM, pH 5.0) 30 mL을 가하여 현탁한 후, 하기 표 5에 따른 각 효소 200㎕를 가하여 45℃에서, 초고압 반응기 DFS-2L (동양고압, 일본)를 이용하여 압력을 0, 30, 50, 80, 100MPa로 조절한 상태에서 12 시간 추출을 행하였다. 상기 추출물에 80% 에탄올 300 mL을 가하여 3시간 동안 환류하여 진세노사이드를 추출하였으며, 이 환류액을 30 mL까지 농축하였다. To 6 g of red ginseng powder purchased from Geumsan, 30 mL of phosphate buffer solution (50 mM, pH 5.0) was added and suspended. Then, 200 μl of each enzyme according to Table 5 was added thereto, and at 45 ° C., an ultrahigh pressure reactor DFS-2L (Oriental High Pressure) was added. , Japan) was extracted for 12 hours while the pressure was adjusted to 0, 30, 50, 80, 100 MPa. 300 mL of 80% ethanol was added to the extract to reflux for 3 hours to extract ginsenosides, and the reflux was concentrated to 30 mL.
Main active
(Novozymes, Dittingen, Switzerland)Ultraflo L
(Novozymes, Dittingen, Switzerland)
이즈Beta-Glucane
Izu
인솔렌즈(H
umicola
insolens) Humi-cola
Insole Lens (H
umicola
insolens)
(DSM, Delft, Netherlands)Rapidase
(DSM, Delft, Netherlands)
셀룰레이즈Pectinase, hemicellulose,
Cellulase
(Novozymes, Dittingen, Switzerland)Viscozyme
(Novozymes, Dittingen, Switzerland)
(Gist-Brocades, Seclin, France)Cytolase PCL 5
(Gist-Brocades, Seclin, France)
(AB Enzymes GmbH, Darmstadt, Germany)Econase CE
(AB Enzymes GmbH, Darmstadt, Germany)
(Trichoder
ma) 속Tricot Derma
Trichoder
ma) genus
효소와 압력을 하기 표 6과 같이 달리하여 비교예들과 실시예들을 준비하였다.Enzyme and pressure were prepared in Comparative Examples and Examples by varying as shown in Table 6 below.
효소pressure
enzyme
<실험예 3: 총당, 산성당, 폴리페놀 및 건물량 측정>Experimental Example 3: Measurement of Total Sugar, Acid Sugar, Polyphenol, and Dry Matter Content
상기 비교예 2 내지 5, 및 실시예 5 내지 실시예 24에 따라 제조된 추출물에 대하여 효소 처리를 하지 아니한 비교예들과 함께 상기 실험예 1에서와 동일한 방법으로 총당, 산성당, 폴리페놀 및 건물양을 측정하였다. 하기 표 7은 총당 함량 변화에 대한 결과이고, 하기 표 8은 산성당 함량 변화에 대한 결과이고, 하기 표 9는 폴리페놀 함량 변화에 대한 결과이고, 하기 표 10은 건물량 변화에 대한 결과이다. Total sugars, acidic sugars, polyphenols and dry matters in the same manner as in Experimental Example 1 together with the comparative examples without enzyme treatment for the extracts prepared according to Comparative Examples 2 to 5, and Examples 5 to 24 The amount was measured. Table 7 is a result of the total sugar content change, Table 8 is a result of the acid sugar content change, Table 9 is a result of the polyphenol content change, Table 10 is a result of the dry matter change.
113.1±10.7bc Comparative Example 2
113.1 ± 10.7 bc
81.2±4.3a Comparative Example 3
81.2 ± 4.3 a
93.6±19.0ab Comparative Example 4
93.6 ± 19.0 ab
76.7±27.9d Comparative Example 5
76.7 ± 27.9 d
148.8±21.1d Example 5
148.8 ± 21.1 d
91.0±11.8ab Example 10
91.0 ± 11.8 ab
71.9±7.5a Example 15
71.9 ± 7.5 a
118.4±19.1cd Example 20
118.4 ± 19.1 cd
197.6±5.6fg Example 6
197.6 ± 5.6 fg
146.5±9.0d Example 11
146.5 ± 9.0 d
161.0±19.0de Example 16
161.0 ± 19.0 de
169.6±25.4ab Example 21
169.6 ± 25.4 ab
155.7±11.1de Example 7
155.7 ± 11.1 de
179.3±24.5ef Example 12
179.3 ± 24.5 ef
188.6±16.2fg Example 17
188.6 ± 16.2 fg
197.0±38.0a Example 22
197.0 ± 38.0 a
187.9±20.8fg Example 8
187.9 ± 20.8 fg
157.9±12.2de Example 13
157.9 ± 12.2 de
214.6±21.0g Example 18
214.6 ± 21.0 g
141.0±25.2bc Example 23
141.0 ± 25.2 bc
137.9±23.2cd Example 9
137.9 ± 23.2 cd
100.0±6.8ab Example 14
100.0 ± 6.8 ab
135.3±6.1cd Example 19
135.3 ± 6.1 cd
126.0±4.03bc Example 24
126.0 ± 4.03 bc
302.0±113.7abc Comparative Example 2
302.0 ± 113.7 abc
185.9±38.1ab Comparative Example 3
185.9 ± 38.1 ab
69.7±15.2ab Comparative Example 4
69.7 ± 15.2 ab
418.8±42.4b Comparative Example 5
418.8 ± 42.4 b
130.3±30.3ab Example 5
130.3 ± 30.3 ab
120.2±97.4ab Example 10
120.2 ± 97.4 ab
29.3±8.8a Example 15
29.3 ± 8.8 a
320.8±194.2b Example 20
320.8 ± 194.2 b
1211.1±162.0gh Example 6
1211.1 ± 162.0 gh
741.4±114.7ef Example 11
741.4 ± 114.7 ef
877.8±83.5ef Example 16
877.8 ± 83.5 ef
365.9±25.0b Example 21
365.9 ± 25.0 b
600.00±84.4cde Example 7
600.00 ± 84.4 cde
1377.8±38.1hi Example 12
1377.8 ± 38.1 hi
1266.7±347.26hi Example 17
1266.7 ± 347.26 hi
1136.5±104.6a Example 22
1136.5 ± 104.6 a
630.3±367.7def Example 8
630.3 ± 367.7 def
731.3±263.5ef Example 13
731.3 ± 263.5 ef
1529.3±86.2i Example 18
1529.3 ± 86.2 i
546.7±120.9b Example 23
546.7 ± 120.9 b
867.7±46.3ef Example 9
867.7 ± 46.3 ef
362.6±126.2bcd Example 14
362.6 ± 126.2 bcd
943.4±319.4fg Example 19
943.4 ± 319.4 fg
528.6±98.7b Example 24
528.6 ± 98.7 b
431.3±17.1b Comparative Example 2
431.3 ± 17.1 b
422.4±12.4b Comparative Example 3
422.4 ± 12.4 b
398.1±8.6ab Comparative Example 4
398.1 ± 8.6 ab
361.8±5.3d Comparative Example 5
361.8 ± 5.3 d
502.5±25.0c Example 5
502.5 ± 25.0 c
503.2±16.4c Example 10
503.2 ± 16.4 c
372.0±28.9a Example 15
372.0 ± 28.9 a
378.7±8.4cd Example 20
378.7 ± 8.4 cd
702.7±27.1gh Example 6
702.7 ± 27.1 gh
708.0±25.2h Example 11
708.0 ± 25.2 h
709.4±41.9h Example 16
709.4 ± 41.9 h
544.8±24.4a Example 21
544.8 ± 24.4 a
651.2±35.2ef Example 7
651.2 ± 35.2 ef
849.0±10.1j Example 12
849.0 ± 10.1 j
874.4±40.6j Example 17
874.4 ± 40.6 j
579.0±39.3a Example 22
579.0 ± 39.3 a
662.5±24.7fg Example 8
662.5 ± 24.7 fg
750.3±18.2i Example 13
750.3 ± 18.2 i
785.5±12.3i Example 18
785.5 ± 12.3 i
419.0±23.8c Example 23
419.0 ± 23.8 c
583.9±14.5d Example 9
583.9 ± 14.5 d
613.5±3.7de Example 14
613.5 ± 3.7 de
664.6±29.8fg Example 19
664.6 ± 29.8 fg
475.3±22.0b Example 24
475.3 ± 22.0 b
8.2±0.2d Comparative Example 2
8.2 ± 0.2 d
6.3±0.2b Comparative Example 3
6.3 ± 0.2 b
6.3±0.1b Comparative Example 4
6.3 ± 0.1 b
7.6±0.07f Comparative Example 5
7.6 ± 0.07 f
8.9±0.2ef Example 5
8.9 ± 0.2 ef
7.2±0.1c Example 10
7.2 ± 0.1 c
5.2±0.1a Example 15
5.2 ± 0.1 a
8.6±0.08e Example 20
8.6 ± 0.08 e
12.3±0.2l Example 6
12.3 ± 0.2 l
8.8±0.4ef Example 11
8.8 ± 0.4 ef
8.7±0.1e Example 16
8.7 ± 0.1 e
10.7±0.1b Example 21
10.7 ± 0.1 b
9.6±0.1g Example 7
9.6 ± 0.1 g
10.6±0.1i Example 12
10.6 ± 0.1 i
10.9±0.2jk Example 17
10.9 ± 0.2 jk
11.1±0.08a Example 22
11.1 ± 0.08 a
10.7±0.2ij Example 8
10.7 ± 0.2 ij
10.1±0.1h Example 13
10.1 ± 0.1 h
11.2±0.5k Example 18
11.2 ± 0.5 k
10.5±0.06c Example 23
10.5 ± 0.06 c
9.6±0.1g Example 9
9.6 ± 0.1 g
7.9±0.1d Example 14
7.9 ± 0.1 d
9.0±0.1f Example 19
9.0 ± 0.1 f
9.2±0.04d Example 24
9.2 ± 0.04 d
상기 표에 나타난 바와 같이, Viscozyme 가수분해물은 압력이 증가할수록 총당의 함량이 증가하는 경향을 보였으며, ultraflo 가수분해물은 압력이 증가할수록 총당의 함량이 감소하는 경향을 보였다(표 7). 산성당의 함량변화에서는 ultraflo, rapidase는 80 MPA 이하의 압력에서는 압력이 증가할수록 함량이 감소하는 경향을 보인 반면, viscozyme, cytolase 가수분해물에서의 산성당 함량은 압력에 따라 증가하는 경향을 보였으며, cytolase의 경우 100 MPa에서는 오히려 산성당의 함량이 감소하는 경향을 보였다. 특히 홍삼의 생리활성 물질중에 여러가지 활성을 지닌 것으로 알려진 산성당의 함량은 효소 처리하지 않고 압력을 가하였을 경우 최고 418.8 ㎍/ml의 함량을 보인 반면, viscozyme과 cytolase 처리하였을 경우 최고 1377.8과 1529.3 ㎍/ml의 함량을 보였다(표 8). As shown in the table, Viscozyme hydrolyzate showed a tendency to increase the total sugar content as the pressure increases, ultraflo hydrolyzate tends to decrease the total sugar content as the pressure increases (Table 7). In the change of acidic sugar content, ultraflo and rapidase tended to decrease with increasing pressure at the pressure below 80 MPA, whereas the acidic sugar content of viscozyme and cytolase hydrolyzate increased with pressure. In case of 100 MPa, the acid sugar content tended to decrease. In particular, the content of acidic sugars, which are known to have various activities in red ginseng, was up to 418.8 ㎍ / ml when applied without enzymatic treatment. The content of was shown (Table 8).
폴리페놀의 함량은 압력만 가하였을 경우 361.8-431.3 ㎍/ml의 함량을 보인 반면, rapidase, viscozyme, cytolase의 경우 각각 544.8-709.4, 579.0-651.2, 419.0-785.5 ㎍/ml의 높은 함량을 보였다(표 9). control의 건물량이 6.3-8.2%인 반면, 효소 가수분해물의 건물량은 5.2-12.3%까지 건물량을 보였으며, viscozyme과 cytolase 가수분해물의 건물량이 비교적 높았다(표 10). Polyphenol content was 361.8-431.3 ㎍ / ml when only pressure was applied, whereas rapid contents of rapidase, viscozyme and cytolase were 544.8-709.4, 579.0-651.2 and 419.0-785.5 ㎍ / ml, respectively. Table 9). The dry matter content of the control was 6.3-8.2%, while the dry matter content of the enzyme hydrolyzate was 5.2-12.3%, and the dry matter content of the viscozyme and cytolase hydrolysates was relatively high (Table 10).
<실험예 4: 실시예 5 내지 9에 대한 진세노사이드 함량의 측정>Experimental Example 4: Determination of Ginsenoside Content for Examples 5-9
상기 실시예 5 내지 9에서 제조된 각 추출물에 대하여 진세노사이드 함량을 측정하였다. 진세노사이드 함량의 측정은 상기 실험예 2와 동일한 방법을 통해 수행되었다. 그 결과는 하기 표와 같다. Ginsenoside content was measured for each extract prepared in Examples 5 to 9. Ginsenoside content was measured in the same manner as in Experimental Example 2. The results are shown in the table below.
(control)Comparative Example 2
(control)
(Ultraflo L)Example 5
(Ultraflo L)
(Rapidase)Example 6
(Rapidase)
(Viscozyme)Example 7
(Viscozyme)
(Cytolase)Example 8
(Cytolase)
(Econase)Example 9
(Econase)
상기 표에 나타난 바와 같이, 30 MPa압력하에서 가수분해한 홍삼 효소 가수분해물의 총 진세노사이드 함량은 비교예2(control)가 17156.7 ㎍/ml인 반면, 효소 가수분해물의 함량은 16948.8-30875.4 ㎍/ml 함량을 보였으며, 가장 높은 함량은 rapidase 가수분해물(실시예6)이 30875.4 ㎍/ml 함량을 보였다. 홍삼제품의 지표물질인 Rg1과 Rb1의 함량이 control(비교예2)은 6318.1 ㎍/mL인데 반하여 효소 가수분해물중 viscozyme (실시예7) 가수분해물은 7276.1 ㎍/mL으로 가장 낮은 함량은 보였으나, rapidase (실시예6) 가수분해물은 12189.9 ㎍/mL으로 가장 높은 함량을 보였다. Rb1, Rb2, Rc 함량은 control(비교예2)이 10425.6 ㎍/mL인 반면, 가수분해물은 11026.9-17599.3 ㎍/mL 함량을 보였다.As shown in the table, the total ginsenoside content of the red ginseng hydrolyzate hydrolyzed at 30 MPa pressure was 17156.7 μg / ml in Comparative Example 2, while the content of enzyme hydrolyzate was 16948.8-30875.4 μg / ml content was shown, the highest content of the rapidase hydrolyzate (Example 6) was 30875.4 ㎍ / ml content. The content of Rg1 and Rb1, the indicators of red ginseng products, was 6318.1 ㎍ / mL in control (Comparative Example 2), while the lowest content of viscozyme (Example 7) hydrolyzate in enzyme hydrolyzate was 7276.1 ㎍ / mL. Rapidase (Example 6) The hydrolyzate showed the highest content of 12189.9 μg / mL. Rb1, Rb2, and Rc contents were 10425.6 µg / mL in the control (Comparative Example 2), while the hydrolyzate showed 11026.9-17599.3 µg / mL.
<실험예 5: 실시예 10 내지 14에 대한 진세노사이드 함량 측정>Experimental Example 5: Determination of ginsenoside content for Examples 10 to 14
상기 실시예 10 내지 14에서 제조된 각 추출물에 대하여 진세노사이드 함량을 측정하였다. 진세노사이드 함량의 측정은 상기 실험예 2와 동일한 방법을 통해 수행되었다. 그 결과는 하기 표와 같다. Ginsenoside content was measured for each extract prepared in Examples 10 to 14. Ginsenoside content was measured in the same manner as in Experimental Example 2. The results are shown in the table below.
(control)Comparative Example 3
(control)
(Ultraflo L)Example 10
(Ultraflo L)
(Rapidase)Example 11
(Rapidase)
(Viscozyme)Example 12
(Viscozyme)
(Cytolase)Example 13
(Cytolase)
(Econase)Example 14
(Econase)
상기 표에 나타난 바와 같이, 50 MPa압력하에서 가수분해한 홍삼 효소 가수분해물의 총 진세노사이드 함량은 control(비교예3)이 19086.1 ㎍/ml인 반면, 효소 가수분해물의 함량은 18060.3-24718.3 ㎍/ml 함량을 보였으며, rapidase 가수분해물(실시예 11)이 가장 높은 함량을 보였다. 홍삼제품의 지표물질인 Rg1과 Rb1의 함량이 control(비교예3)은 7162.5 ㎍/mL인데 반하여 효소 가수분해물중 cytolase 가수분해물(실시예13)은 5932.3 ㎍/mL으로 가장 낮은 함량은 보였으나, viscozyme 가수분해물(실시예12)은 9540.4 ㎍/mL으로 가장 높은 함량을 보였다. Rb1, Rb2, Rc 함량은 control(비교예3)이 11901.2 ㎍/mL인 반면, 가수분해물은 8926.3-15745.6 ㎍/mL 함량을 보였다. Viscozyme 가수분해물(실시예12)이 가장 높은 함량을 보였다(표 11). 50 MPa에서 반응 시 30 MPa에서는 측정되지 않았던 Rg3가 rapidase (실시예11), viscozyme(실시예12), cytolase(실시예13), econase(실시예14) 가수분해물에서는 각각 940.7, 943.5, 804.6, 711.9 ㎍/mL 함량을 보였다. As shown in the table, the total ginsenoside content of the red ginseng enzymatic hydrolyzate hydrolyzed under 50 MPa pressure was 19086.1 μg / ml for the control (Comparative Example 3), while the content of the enzyme hydrolyzate was 18060.3-24718.3 μg /. ml content was shown, and rapidase hydrolyzate (Example 11) had the highest content. The content of Rg1 and Rb1, which are indicators of red ginseng products, was 7162.5 ㎍ / mL in control (Comparative Example 3), whereas the lowest content of cytolase hydrolyzate (Example 13) was 5932.3 ㎍ / mL in enzyme hydrolyzate. The viscozyme hydrolyzate (Example 12) had the highest content of 9540.4 μg / mL. The Rb1, Rb2, and Rc contents were 11901.2 µg / mL in the control (Comparative Example 3), while the hydrolyzate showed 8926.3-15745.6 µg / mL. Viscozyme hydrolyzate (Example 12) showed the highest content (Table 11). Rg3 which was not measured at 30 MPa when reacted at 50 MPa was rapidase (Example 11), viscozyme (Example 12), cytolase (Example 13), econase (Example 14) in hydrolysates 940.7, 943.5, 804.6, 711.9 μg / mL was shown.
<실험예 6: 실시예 15 내지 19에 대한 진세노사이드 함량 측정>Experimental Example 6: Determination of ginsenoside content for Examples 15 to 19
상기 실시예 15 내지 19에서 제조된 각 추출물에 대하여 진세노사이드 함량을 측정하였다. 진세노사이드 함량의 측정은 상기 실험예 2와 동일한 방법을 통해 수행되었다. 그 결과는 하기 표와 같다. Ginsenoside content was measured for each extract prepared in Examples 15 to 19. Ginsenoside content was measured in the same manner as in Experimental Example 2. The results are shown in the table below.
(control)Comparative Example 4
(control)
(Ultraflo L)Example 15
(Ultraflo L)
(Rapidase)Example 16
(Rapidase)
(Viscozyme)Example 17
(Viscozyme)
(Cytolase)Example 18
(Cytolase)
(Econase)Example 19
(Econase)
상기 표에 나타난 바와 같이, 80 MPa압력하에서 가수분해한 홍삼 효소 가수분해물의 총 진세노사이드 함량은 control(비교예1)이 23075.5 ㎍/ml인 반면, 효소 가수분해물의 함량은 14479.0-31362.6 ㎍/ml 함량을 보였으며, econase 가수분해물(실시예19)이 가장 높은 함량을 보였다. 홍삼제품의 지표물질인 Rg1과 Rb1의 함량이 control(비교예4)은 8676.0 ㎍/mL인데 반하여 효소 가수분해물중 ultraflo(실시예15), rapidase(비교예16), cytolase(비교예18) 가수분해물은 각각 4203.7, 8413.5, 8550.5 ㎍/mL로 control (비교예4) 보다 낮은 함량은 보였으나, viscozyme(실시예17)과 econase 가수분해물(실시예19)은 11069.3과 10737.7 ㎍/mL으로 control(비교예4) 보다 높은 함량을 보였다. Rb1, Rb2, Rc 함량은 control(비교예4)이 15224.0 ㎍/mL인 반면, 가수분해물은 8436.8-19417.6 ㎍/mL 함량을 보였다. Econase 가수분해물(실시예19)이 가장 높은 함량을 보였다(표 12). 50 MPa에서 반응 시 Rg3가 측정되지 않았던 ultraflo 가수분해물도 80 MPa 반응 시(실시예15) 507.3 ㎍/mL를 함유하고 있으며, rapidase(실시예16), viscozyme(실시예17), cytolase(실시예18), econase(실시예19) 가수분해물에서는 각각 963.2, 1131.9, 985.8, 1026.4 ㎍/mL 함량을 보였다. As shown in the table, the total ginsenoside content of red ginseng hydrolyzate hydrolyzed under 80 MPa pressure was 23075.5 μg / ml in control (Comparative Example 1), while the content of enzyme hydrolyzate was 14479.0-31362.6 μg / ml content was shown and econase hydrolyzate (Example 19) showed the highest content. The contents of Rg1 and Rb1, the indicators of red ginseng products, were 8676.0 ㎍ / mL in control (Comparative Example 4), whereas ultraflo (Example 15), rapidase (Comparative Example 16) and cytolase (Comparative Example 18) Degradates were 4203.7, 8413.5, and 8550.5 ㎍ / mL, respectively, lower than control (Comparative Example 4), but viscozyme (Example 17) and econase hydrolyzate (Example 19) were 11069.3 and 10737.7 ㎍ / mL, respectively. Comparative Example 4 showed a higher content. Rb1, Rb2, Rc content was 15224.0 μg / mL in control (Comparative Example 4), while hydrolyzate showed 8436.8-19417.6 μg / mL. Econase hydrolyzate (Example 19) showed the highest content (Table 12). The ultraflo hydrolyzate, in which Rg3 was not measured at 50 MPa, also contained 507.3 μg / mL at 80 MPa reaction (Example 15), rapidase (Example 16), viscozyme (Example 17), cytolase (Example 18), econase (Example 19) the hydrolyzate showed 963.2, 1131.9, 985.8, 1026.4 ㎍ / mL content, respectively.
<실험예 7: 실시예 20 내지 24에 대한 진세노사이드 함량 측정>Experimental Example 7: Determination of ginsenoside content for Examples 20 to 24
상기 실시예 20 내지 24에서 제조된 각 추출물에 대하여 진세노사이드 함량을 측정하였다. 진세노사이드 함량의 측정은 상기 실험예 2와 동일한 방법을 통해 수행되었다. 그 결과는 하기 표와 같다. Ginsenoside content was measured for each extract prepared in Examples 20 to 24. Ginsenoside content was measured in the same manner as in Experimental Example 2. The results are shown in the table below.
controlComparative Example 5
control
Ultraflo LExample 20
Ultraflo L
RapidaseExample 21
Rapidase
ViscozymeExample 22
Viscozyme
Cytolase PCL 5Example 23
Cytolase PCL 5
Econitase CEExample 24
Econitase CE
상기 표에 나타난 바와 같이, 100 MPa 압력하에서 가수분해한 홍삼 효소 가수분해물의 총 진세노사이드 함량은 control(비교예5)이 29367.5 ㎍/ml인 반면, 효소 가수분해물의 함량은 38790.0-63335.7 ㎍/ml 함량을 보였으며, cytolase 가수분해물(실시예23)이 가장 높은 함량을 보였다. 홍삼제품의 지표물질인 Rg1과 Rb1의 함량이 control(비교예5)은 9976.1 ㎍/mL인데 반하여 효소 가수분해물은 11374.9-26731.1 ㎍/mL이 었으며, cytolase 가수분해물(실시예23)인 가장 높은 함량을 보였다. Rb1, Rb2, Rc 함량은 control(비교예5)이 17217.4 ㎍/mL였으며, rapidase 가수분해물(실시예21)은 19318.0 ㎍/mL으로 효소 가수분해물중 가장 낮은 함량을 보였다. Cytolase 가수분해물(실시예23)은 46756.3 ㎍/mL으로 가장 높은 함량을 보였다. Rg2의 함량은 control(비교예5)이 322.4 ㎍/mL 이었으나, 효소 가수분해물은 183.6-304.6 ㎍/mL의 높은 함량을 보였으며, 이중 cytolase 가수분해물(실시예23)이 가장 높은 함량을 보였다.As shown in the table, the total ginsenoside content of the red ginseng hydrolyzate hydrolyzed under 100 MPa pressure was 29367.5 µg / ml in control (Comparative Example 5), while the content of enzyme hydrolyzate was 38790.0-63335.7 µg /. It showed the ml content, cytolase hydrolyzate (Example 23) showed the highest content. The contents of Rg1 and Rb1, which are indicators of red ginseng products, were 9976.1 ㎍ / mL for control (Comparative Example 5), while the enzyme hydrolyzate was 11374.9-26731.1 ㎍ / mL, and the highest content of cytolase hydrolyzate (Example 23). Showed. Rb1, Rb2, and Rc contents were 17217.4 µg / mL in the control (Comparative Example 5), and rapidase hydrolyzate (Example 21) was 19318.0 µg / mL, which was the lowest in the enzyme hydrolyzate. Cytolase hydrolyzate (Example 23) showed the highest content of 46756.3 μg / mL. The content of Rg2 was 322.4 μg / mL in the control (Comparative Example 5), but the enzyme hydrolyzate showed a high content of 183.6-304.6 μg / mL, and the highest cytolase hydrolyzate (Example 23).
<실시예 25 내지 44: 감마 사이클로덱스트린이 첨가된 조성물><Examples 25 to 44: A composition to which gamma cyclodextrin is added>
상기 실시예 5 내지 24에 따라 제조된 각 홍삼 농축액 100 중량부에 대하여 7중량부에 해당하는 감마 사이클로덱스트린인 Cavamax® W8 food(WACKER, Germany)을 더 첨가하였다. To 100 parts by weight of each red ginseng concentrate prepared according to Examples 5 to 24, 7 parts by weight of a gamma cyclodextrin corresponding to Cavamax® W8 food (WACKER, Germany) was further added.
이하 본 발명의 조성물을 제형예를 들어 설명하나, 이는 본 발명을 한정하고자 함이 아니라 단지 구체적으로 설명하고자 함이다. Hereinafter, the composition of the present invention will be described by way of example, but it is not intended to limit the present invention but merely to explain in detail.
<제형예 1: 연질 캅셀제><Formulation Example 1: Soft Capsule>
상기 실시예 5 내지 24에 따라 제조된 홍삼농축액 50mg, L-카르니틴 80~140mg, 대두유 180mg, 팜유 2mg, 식물성 경화유 8mg, 황납 4mg 및 레시틴 6mg을 혼합하고, 통상의 방법에 따라 1캡슐당 400mg씩 충진하여 연질캅셀을 제조하였다.Red ginseng concentrate prepared according to Examples 5 to 24 50mg, L-carnitine 80 ~ 140mg, soybean oil 180mg, palm oil 2mg, vegetable hardened oil 8mg, lead 4mg and lecithin 6mg, 400mg per capsule according to a conventional method Filled to prepare a soft capsule.
<제형예 2: 정제><Formulation Example 2: Tablet>
상기 실시예 25 내지 44에 따라 제조된 홍삼농축액 50mg, 갈락토올리고당 200mg, 유당 60mg 및 맥아당 140mg을 혼합하고 유동층 건조기를 이용하여 과립한 후 당 에스테르(sugar ester)를 6mg을 첨가하여 타정기로 타정하여 정제를 제조하였다.50 mg of red ginseng concentrate prepared according to Examples 25 to 44, 200 mg of galactooligosaccharide, 60 mg of lactose and 140 mg of maltose were mixed and granulated using a fluidized bed dryer, followed by granulating with a tablet press by adding 6 mg of sugar ester. Tablets were prepared.
<제형예 3: 과립제><Formulation Example 3: Granules>
상기 실시예 5 내지 24에 따라 제조된 홍삼농축액 50mg, 무수결정 포도당 250mg 및 전분 550mg을 혼합하고, 유동층 과립기를 사용하여 과립으로 성형한 후 포에 충진하였다. 50 mg of red ginseng concentrate prepared according to Examples 5 to 24, 250 mg of anhydrous glucose, and 550 mg of starch were mixed and molded into granules by using a fluidized bed granulator, and then filled into fabric.
<제형예 4: 드링크제><Formulation example 4: drink system>
상기 실시예 25 내지 44에 따라 제조된 홍삼농축액 50mg, 포도당 10g, 구연산 0.6g, 및 액상 올리고당 25g을 혼합한 후 정제수 300ml를 가하여 각 병에 200ml씩 충진한다. 병에 충진한 후 130℃ 에서 4??5 초간 살균하여 음료를 제조하였다. 50 mg of red ginseng concentrate prepared according to Examples 25 to 44, 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharides were mixed, and 300 ml of purified water was added thereto, and 200 ml were filled in each bottle. After filling the bottle sterilized for 4 ?? 5 seconds at 130 ℃ to prepare a beverage.
<제형예 5: 캬라멜 제형>Formulation Example 5 Caramel Formulations
상기 실시예 25 내지 44에 따라 제조된 홍삼농축액 50mg, 옥수수 시럽(corn syrup) 1.8g, 탈지우유 0.5g, 대두 레시틴 0.5g, 버터 0.6g, 식물성 경화유 0.4g, 설탕 1.4g, 마가린 0.58g, 및 식염 20mg을 혼합하여 캬라멜 성형을 하였다. Red ginseng concentrate prepared in accordance with Examples 25 to 44 50mg, corn syrup (corn syrup) 1.8g, skim milk 0.5g, soy lecithin 0.5g, butter 0.6g, vegetable hardened milk 0.4g, sugar 1.4g, margarine 0.58g, And 20 mg of salt was mixed to form caramel.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080012278A KR100970455B1 (en) | 2008-02-11 | 2008-02-11 | Method for preparing extract of ginseng using ultra high pressure |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080012278A KR100970455B1 (en) | 2008-02-11 | 2008-02-11 | Method for preparing extract of ginseng using ultra high pressure |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090086806A KR20090086806A (en) | 2009-08-14 |
KR100970455B1 true KR100970455B1 (en) | 2010-07-16 |
Family
ID=41206031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080012278A KR100970455B1 (en) | 2008-02-11 | 2008-02-11 | Method for preparing extract of ginseng using ultra high pressure |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100970455B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150034444A (en) * | 2013-09-26 | 2015-04-03 | 샘표식품 주식회사 | Ginseng or mountain ginseng containing improved ginsenoside and aglycon, and method for processing thereof |
KR20230029011A (en) | 2021-08-23 | 2023-03-03 | 주식회사 한빛향료 | The method and the extract of extracting acidic polysaccharides from red ginseng residue or black ginseng residue, manufactured using ultra-high pressure treatment, using high-temperature and high-pressure water |
KR20230029010A (en) | 2021-08-23 | 2023-03-03 | 주식회사 한빛향료 | The method and the extract of extracting ginsenosides from red ginseng or black ginseng, manufactured using ultra-high pressure treatment, using high-temperature and high-pressure water |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101065956B1 (en) * | 2008-12-16 | 2011-09-19 | 주식회사 동원에프앤비 | A method for processing red ginseng by enzyme and high hydrostatic pressure |
KR101328413B1 (en) * | 2011-09-09 | 2013-11-14 | 주식회사 이노웨이 | An extracting method of ginseng by high pressure/enzyme decomposition |
KR101360961B1 (en) * | 2012-01-30 | 2014-02-12 | 전주대학교 산학협력단 | Method for preparing boiled salt comprising Red Ginseng |
KR101412682B1 (en) * | 2013-04-26 | 2014-08-14 | 주식회사 엔씨 | Manufacturing method of red ginseng extract |
KR101397145B1 (en) * | 2014-02-26 | 2014-05-19 | 양양군 | Method for obtaining extract of raw ginseng and raw ginseng at the same time |
CN108185429A (en) * | 2017-05-20 | 2018-06-22 | 郑毅男 | A kind of method using extra-high tension unit extraction fresh ginseng and its purposes in healthy food |
KR102099345B1 (en) * | 2017-12-04 | 2020-04-09 | 서울대학교산학협력단 | Method for High-yield extraction of ginsenoside from ginseng and ginsenoside extracted by the same |
KR102322628B1 (en) * | 2021-02-26 | 2021-11-04 | 이유정 | A method for preparing wild ginseng cultured root extract with increased content of specific ginsenosides and cosmetic composition for relieving hair loss symptoms and promoting hair growth using ginsenoside complexes |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020040533A (en) * | 2001-05-15 | 2002-05-30 | 카부시키가이샤토오요오핫코오 | Method of lowering molecular weight of effective components in Red Ginseng Extract |
KR100445184B1 (en) * | 2002-05-08 | 2004-08-21 | 주식회사 그린바이오텍 | A method for processing Ginseng by Ultra-high pressure |
KR20060119384A (en) * | 2005-05-20 | 2006-11-24 | (주)아모레퍼시픽 | A oral composition for improving beauty of skin |
-
2008
- 2008-02-11 KR KR1020080012278A patent/KR100970455B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020040533A (en) * | 2001-05-15 | 2002-05-30 | 카부시키가이샤토오요오핫코오 | Method of lowering molecular weight of effective components in Red Ginseng Extract |
KR100445184B1 (en) * | 2002-05-08 | 2004-08-21 | 주식회사 그린바이오텍 | A method for processing Ginseng by Ultra-high pressure |
KR20060119384A (en) * | 2005-05-20 | 2006-11-24 | (주)아모레퍼시픽 | A oral composition for improving beauty of skin |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150034444A (en) * | 2013-09-26 | 2015-04-03 | 샘표식품 주식회사 | Ginseng or mountain ginseng containing improved ginsenoside and aglycon, and method for processing thereof |
KR101591251B1 (en) | 2013-09-26 | 2016-02-03 | 샘표식품 주식회사 | Ginseng or mountain ginseng containing improved ginsenoside and aglycon, and method for processing thereof |
KR20230029011A (en) | 2021-08-23 | 2023-03-03 | 주식회사 한빛향료 | The method and the extract of extracting acidic polysaccharides from red ginseng residue or black ginseng residue, manufactured using ultra-high pressure treatment, using high-temperature and high-pressure water |
KR20230029010A (en) | 2021-08-23 | 2023-03-03 | 주식회사 한빛향료 | The method and the extract of extracting ginsenosides from red ginseng or black ginseng, manufactured using ultra-high pressure treatment, using high-temperature and high-pressure water |
Also Published As
Publication number | Publication date |
---|---|
KR20090086806A (en) | 2009-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100970455B1 (en) | Method for preparing extract of ginseng using ultra high pressure | |
JP5528718B2 (en) | Glucan composition elevation inhibitor and insulin secretagogue using β-glucan composition | |
KR100479803B1 (en) | Composition containing an extract of specially treated ginseng for preventing brain cells and treating brain stroke | |
JP4777776B2 (en) | Ginseng preparation using vinegar and method for producing the same | |
US20020018818A1 (en) | Sugar decomposition inhibitor, digestive enzyme activity inhibitor, insulin secretion controller, and healthy food and beverage | |
CN103977409A (en) | Dietary supplement composition and blood sugar regulating method thereof | |
KR100949247B1 (en) | Method for producing processed ginseng or processed ginseng extract | |
KR20100018018A (en) | Method for producing processed ginseng or processed ginseng extract | |
KR20060000488A (en) | Composition containing ginseng extract comprising saponin derivatives isolated from ginseng radix and ginseng for preventing and treating scratching diseases | |
KR101750779B1 (en) | Composition for anti-fatigue containing aglycone ppd and/or ppt | |
CN110859869A (en) | A composition for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method | |
KR101530982B1 (en) | Preparing method of immuno-stimulating activities of polysaccharide fractions isolated and aglycon flavonoid from citrus peel | |
KR20110093477A (en) | Antitumor composition comprising fermented red ginseng | |
KR100759772B1 (en) | A COMPOSITION CONTAINING GENSENOSIDE Rh2 AS AN ACTIVE MATERIAL FOR PREVENTING BRAIN CELL | |
KR20030080296A (en) | Composition containing saponin fraction and derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
KR101975018B1 (en) | Composition for lowering cholesterol comprising a mixture culture of Ginseng Berry-Auricularia auricula mycelia | |
KR101787082B1 (en) | Composition comprising the extract of Platycodon grandiflorum enhanced effective saponin contents for treatment of rheumatoid arthritis | |
US20240123019A1 (en) | Composition for treating or ameliorating liver disease and liver dysfunction comprising zizania latifolia extract | |
KR101620160B1 (en) | Composition for the prevention or treatment of Inflammatory Bowel Disease comprising extract of Atractylodes spp, and Poncirus trifoliata | |
US9101648B2 (en) | Pharmaceutical composition comprising mannooligosaccharides derived from coffee for treatment of lifestyle-related disease, and food useful for treatment of lifestyle-related disease | |
KR101975017B1 (en) | Composition for lowering cholesterol comprising a mixture culture of Ginseng Berry-hongguk | |
KR101989980B1 (en) | Anticancer or immunactive polysaccharide from residues of immature citrus extract or immature citrus peel and composition comprising the same as an active ingredient | |
KR101935200B1 (en) | Novel Compound Hexadecaphlorethol Isolated from Ishige okamurae and Composition for Anti-Diabetes Using the Same | |
Long | Preparation And Application of Α-Amylase Inhibitors | |
KR100456417B1 (en) | Composition containing an extract of specially treated ginseng for preventing brain cells and treating brain stroke |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130708 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140708 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150708 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160708 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170710 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180709 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190708 Year of fee payment: 10 |